Qian Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Qian Wang has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Qian Huang
Department of Obstetrics and Gynecology, The 75th Group Army Hospital, Dali, China
6 shared publicationsNing Liang
Department of General Surgery, The 75th Group Army Hospital, Dali, China
5 shared publicationsTao Yang
Department of Interventional Radiology, Tangdu Hospital, Fourth Military Medical University, Xi’an, China
5 shared publicationsJing Li
State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi Clinical Research Center for Oral Diseases, Department of Oral and Maxillofacial Surgery, School of Stomatology, Fourth Military Medical University, Xi’an, China
4 shared publications- Xianli He
Department of General Surgery, Tangdu Hospital, Air Force Military Medical University, Xi’an, China
4 shared publications Chaoxu Liu
Department of Colorectal Surgery, The First Affiliated Hospital of Zhejiang University, Hangzhou, China
3 shared publications
Latest Publications
- Open Access
- 10 April 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
SLC25A1 upregulation promotes HNSCC cisplatin resistance via H3K27ac-mediated cellular senescence
Chemoresistance to cisplatin is a major contributor to the progression of head and neck squamous cell carcinoma (HNSCC); however, the mechanisms underlying cisplatin resistance in HNSCC remain incompletely understood. Dysregulation of metabolite transport between mitochondria and the cytoplasm, mediated by solute carrier family 25 (SLC25), is closely associated with tumor progression. Solute carrier family 25 member 1 (SLC25A1) promotes malignant phenotypes in various cancers; however, its role in HNSCC remains unexplored. Here, we demonstrate that SLC25A1 is overexpressed in HNSCC and is closely associated with poor prognosis. SLC25A1 upregulation promotes cisplatin resistance in HNSCC cells. Moreover, SLC25A1 enhances cisplatin resistance in HNSCC cells by inducing cellular senescence. Mechanistically, SLC25A1 upregulates the expression of RANBP1, CDC45, and PES1 through histone H3 lysine 27 acetylation–mediated transcriptional activation. Furthermore, SLC25A1 interacts with HSPD1, a mitochondrial chaperonin protein, via its C-terminal region to increase citrate transport and cytosolic acetyl-CoA levels. Treatment with CTPI-2, a specific inhibitor of SLC25A1, exhibits therapeutic effects against cisplatin-resistant HNSCC. These findings establish SLC25A1 as a key regulator of cisplatin resistance in HNSCC, suggesting that it serves as both a predictive biomarker and a potential therapeutic target in chemoresistant HNSCC. From a translational perspective, these results support CTPI-2 as a promising therapeutic agent for overcoming cisplatin resistance.
- 10 April 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Open AccessSLC25A1 upregulation promotes HNSCC cisplatin resistance via H3K27ac-mediated cellular senescence
Chemoresistance to cisplatin is a major contributor to the progression of head and neck squamous cell carcinoma (HNSCC); however, the mechanisms underlying cisplatin resistance in HNSCC remain incompletely understood. Dysregulation of metabolite transport between mitochondria and the cytoplasm, mediated by solute carrier family 25 (SLC25), is closely associated with tumor progression. Solute carrier family 25 member 1 (SLC25A1) promotes malignant phenotypes in various cancers; however, its role in HNSCC remains unexplored. Here, we demonstrate that SLC25A1 is overexpressed in HNSCC and is closely associated with poor prognosis. SLC25A1 upregulation promotes cisplatin resistance in HNSCC cells. Moreover, SLC25A1 enhances cisplatin resistance in HNSCC cells by inducing cellular senescence. Mechanistically, SLC25A1 upregulates the expression of RANBP1, CDC45, and PES1 through histone H3 lysine 27 acetylation–mediated transcriptional activation. Furthermore, SLC25A1 interacts with HSPD1, a mitochondrial chaperonin protein, via its C-terminal region to increase citrate transport and cytosolic acetyl-CoA levels. Treatment with CTPI-2, a specific inhibitor of SLC25A1, exhibits therapeutic effects against cisplatin-resistant HNSCC. These findings establish SLC25A1 as a key regulator of cisplatin resistance in HNSCC, suggesting that it serves as both a predictive biomarker and a potential therapeutic target in chemoresistant HNSCC. From a translational perspective, these results support CTPI-2 as a promising therapeutic agent for overcoming cisplatin resistance.
- Open Access
- 4 April 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Regulating the dormancy of cancer stem cells: a novel approach to preventing cancer relapse
Dormant cancer stem cells (CSCs) are the root cause of the drug resistance and metastatic processes of malignant tumors, but an in-depth analysis of their biological mechanisms is needed. Dormant CSCs are in the G0 phase of the cell cycle and are characterized by enhanced autophagic activity, a stable genomic structure and strong plasticity. Recently, several new specific markers of dormant CSCs, such as p27, CD13, QSOX1, Survivin, GPD1 and BEX2, have been identified, which offer hope for targeted therapy. In addition, epigenetic modifications such as DNA methylation and histone modifications have been reported to regulate the transition between the quiescent and proliferative states of dormant CSCs. From a clinical perspective, keeping cancer stem cells in a dormant state is helpful for preventing tumor recurrence and metastasis. To this end, clarifying the potential mechanisms and molecular regulation of cancer stem cell dormancy is vital. Here, in this review, we examine recent significant findings regarding tumor stem cell dormancy in both experimental and human disease models, emphasizing the underlying molecular mechanisms, regulatory processes, experimental models, and prospective research directions aimed at advancing this field and enhancing clinical translation.
- 4 April 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessRegulating the dormancy of cancer stem cells: a novel approach to preventing cancer relapse
Dormant cancer stem cells (CSCs) are the root cause of the drug resistance and metastatic processes of malignant tumors, but an in-depth analysis of their biological mechanisms is needed. Dormant CSCs are in the G0 phase of the cell cycle and are characterized by enhanced autophagic activity, a stable genomic structure and strong plasticity. Recently, several new specific markers of dormant CSCs, such as p27, CD13, QSOX1, Survivin, GPD1 and BEX2, have been identified, which offer hope for targeted therapy. In addition, epigenetic modifications such as DNA methylation and histone modifications have been reported to regulate the transition between the quiescent and proliferative states of dormant CSCs. From a clinical perspective, keeping cancer stem cells in a dormant state is helpful for preventing tumor recurrence and metastasis. To this end, clarifying the potential mechanisms and molecular regulation of cancer stem cell dormancy is vital. Here, in this review, we examine recent significant findings regarding tumor stem cell dormancy in both experimental and human disease models, emphasizing the underlying molecular mechanisms, regulatory processes, experimental models, and prospective research directions aimed at advancing this field and enhancing clinical translation.
- 15 September 2023
- Published by Springer Nature in British Journal of Cancer
- Vol. 129 (9) , 1477-1489
BEX1 supports the stemness of hepatoblastoma by facilitating Warburg effect in a PPARγ/PDK1 dependent manner
Background Hepatoblastoma (HB) is a highly aggressive paediatric malignancy that exhibits a high presence of cancer stem cells (CSCs), which related to tumour recurrence and chemotherapy resistance. Brain expressed X-linked protein 1 (BEX1) plays a pivotal role in ciliogenesis, axon regeneration and differentiation of neural stem cells. However, the role of BEX1 in metabolic and stemness programs in HB remains unclear. Methods BEX1 expression in human and mouse HB was analyzed using gene expression profile data from NCBI GEO and immunohistochemical validation. Seahorse extracellular flux analyzer, ultra-high-performance liquid-chromatography mass spectrometry (LC-MS), flow cytometry, qRT-PCR, Western Blot, sphere formation assay, and diluted xenograft tumour formation assay were used to analyze metabolic and stemness features. Results Our results indicated that overexpression of BEX1 significantly enhanced the Warburg effect in HB cells. Furthermore, glycolysis inhibition largely attenuated the effects of BEX1 on HB cell growth and self-renewal, suggesting that BEX1 promotes stemness maintenance of HB cells by regulating the Warburg effect. Mechanistically, BEX1 enhances Warburg effect through the downregulation of peroxisome proliferator-activated receptor-gamma (PPARγ). Furthermore, pyruvate dehydrogenase kinase isozyme 1 (PDK1) is required for PPARγ-induced inhibition of Warburg effect in HB. In addition, BEX1 supports the stemness of HB by enhancing Warburg effect in a PPARγ/PDK1 dependent manner. Conclusions HB patients with high BEX1 and PDK1 expression had a poor prognosis. BEX1 promotes the stemness maintenance of HB cells via modulating the Warburg effect, which depends on PPARγ/PDK1 axis. Pioglitazone could be used to target BEX1-mediated stemness properties in HB by upregulating PPARγ.
- 15 September 2023
- Published by Springer Nature in British Journal of Cancer
- Vol. 129 (9) , 1477-1489
BEX1 supports the stemness of hepatoblastoma by facilitating Warburg effect in a PPARγ/PDK1 dependent manner
Background Hepatoblastoma (HB) is a highly aggressive paediatric malignancy that exhibits a high presence of cancer stem cells (CSCs), which related to tumour recurrence and chemotherapy resistance. Brain expressed X-linked protein 1 (BEX1) plays a pivotal role in ciliogenesis, axon regeneration and differentiation of neural stem cells. However, the role of BEX1 in metabolic and stemness programs in HB remains unclear. Methods BEX1 expression in human and mouse HB was analyzed using gene expression profile data from NCBI GEO and immunohistochemical validation. Seahorse extracellular flux analyzer, ultra-high-performance liquid-chromatography mass spectrometry (LC-MS), flow cytometry, qRT-PCR, Western Blot, sphere formation assay, and diluted xenograft tumour formation assay were used to analyze metabolic and stemness features. Results Our results indicated that overexpression of BEX1 significantly enhanced the Warburg effect in HB cells. Furthermore, glycolysis inhibition largely attenuated the effects of BEX1 on HB cell growth and self-renewal, suggesting that BEX1 promotes stemness maintenance of HB cells by regulating the Warburg effect. Mechanistically, BEX1 enhances Warburg effect through the downregulation of peroxisome proliferator-activated receptor-gamma (PPARγ). Furthermore, pyruvate dehydrogenase kinase isozyme 1 (PDK1) is required for PPARγ-induced inhibition of Warburg effect in HB. In addition, BEX1 supports the stemness of HB by enhancing Warburg effect in a PPARγ/PDK1 dependent manner. Conclusions HB patients with high BEX1 and PDK1 expression had a poor prognosis. BEX1 promotes the stemness maintenance of HB cells via modulating the Warburg effect, which depends on PPARγ/PDK1 axis. Pioglitazone could be used to target BEX1-mediated stemness properties in HB by upregulating PPARγ.
- 12 June 2023
- Published by Elsevier in Metabolism
- Vol. 147, 155628
OCTN2 enhances PGC-1α-mediated fatty acid oxidation and OXPHOS to support stemness in hepatocellular carcinoma
- 12 June 2023
- Published by Elsevier in Metabolism
- Vol. 147, 155628
OCTN2 enhances PGC-1α-mediated fatty acid oxidation and OXPHOS to support stemness in hepatocellular carcinoma
- 8 December 2022
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1878 (1) , 188846
Intratumoral bacteria are an important “accomplice” in tumor development and metastasis
- 8 December 2022
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1878 (1) , 188846
Intratumoral bacteria are an important “accomplice” in tumor development and metastasis
- 11 September 2022
- Published by Elsevier in Cancer Letters
- Vol. 549, 215912
Mitochondrial fragmentation in liver cancer: Emerging player and promising therapeutic opportunities
- 11 September 2022
- Published by Elsevier in Cancer Letters
- Vol. 549, 215912
Mitochondrial fragmentation in liver cancer: Emerging player and promising therapeutic opportunities
- 4 May 2022
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 65, 39-50
MDSCs might be “Achilles heel” for eradicating CSCs
- 4 May 2022
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 65, 39-50
MDSCs might be “Achilles heel” for eradicating CSCs
- Open Access
- 21 April 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (4) , 1-14
Mechanism of cancer stemness maintenance in human liver cancer
Primary liver cancer mainly includes the following four types: hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), hepatoblastoma (HB), and combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CCA). Recent studies have indicated that there are differences in cancer stem cell (CSC) properties among different types of liver cancer. Liver cancer stem cells (LCSCs), also called liver tumor-initiating cells, have been viewed as drivers of tumor initiation and metastasis. Many mechanisms and factors, such as mitophagy, mitochondrial dynamics, epigenetic modifications, the tumor microenvironment, and tumor plasticity, are involved in the regulation of cancer stemness in liver cancer. In this review, we analyze cancer stemness in different liver cancer types. Moreover, we further evaluate the mechanism of cancer stemness maintenance of LCSCs and discuss promising treatments for eradicating LCSCs.
- 21 April 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (4) , 1-14
Open AccessMechanism of cancer stemness maintenance in human liver cancer
Primary liver cancer mainly includes the following four types: hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), hepatoblastoma (HB), and combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CCA). Recent studies have indicated that there are differences in cancer stem cell (CSC) properties among different types of liver cancer. Liver cancer stem cells (LCSCs), also called liver tumor-initiating cells, have been viewed as drivers of tumor initiation and metastasis. Many mechanisms and factors, such as mitophagy, mitochondrial dynamics, epigenetic modifications, the tumor microenvironment, and tumor plasticity, are involved in the regulation of cancer stemness in liver cancer. In this review, we analyze cancer stemness in different liver cancer types. Moreover, we further evaluate the mechanism of cancer stemness maintenance of LCSCs and discuss promising treatments for eradicating LCSCs.
- 1 December 2021
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 55, 151828
Histopathological evidence of intrahepatic cholangiocarcinoma occurring in ductal plate malformation: A clinicopathologic study of 5 cases
- 1 December 2021
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 55, 151828
Histopathological evidence of intrahepatic cholangiocarcinoma occurring in ductal plate malformation: A clinicopathologic study of 5 cases
- 27 July 2021
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 18 (2) , E157-E162
Clinical significance and prognostic value of circulating B10 cells in colorectal cancer
Background: B10 cells, a subset of regulatory B cells, can inhibit antitumor response and thus promote tumor development. This study explored the clinical meaning and prognostic value of circulating B10 cells in colorectal cancer (CRC).Materials and methods: The proportion of B10 cells in peripheral blood in CRC patients and healthy controls was detected by multicolor flow cytometry.Results: The proportion of circulating B10 cells was remarkably elevated in CRC patients compared to normal controls (% of CD19+B cells; 16.6% (IQR 6.0%) versus 9.0% (IQR 5.7%), p < 0.001). B10 cells proportion was associated with tumor size, depth of invasion, lymph node metastasis, and TNM stage in CRC. Kaplan–Meier analysis indicated that CRC patients with high B10 cells proportion suffered worse overall survival than those with low B10 cells proportion. Multivariate analysis revealed that the proportion of B10 cells was an independent prognostic indicator for CRC patients.Conclusion: Our results indicate that the proportion of circulating B10 cells is an independent prognostic factor for patients with CRC and thus may help guide the clinical decision in CRC.
- 27 July 2021
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 18 (2) , E157-E162
Clinical significance and prognostic value of circulating B10 cells in colorectal cancer
Background: B10 cells, a subset of regulatory B cells, can inhibit antitumor response and thus promote tumor development. This study explored the clinical meaning and prognostic value of circulating B10 cells in colorectal cancer (CRC).Materials and methods: The proportion of B10 cells in peripheral blood in CRC patients and healthy controls was detected by multicolor flow cytometry.Results: The proportion of circulating B10 cells was remarkably elevated in CRC patients compared to normal controls (% of CD19+B cells; 16.6% (IQR 6.0%) versus 9.0% (IQR 5.7%), p < 0.001). B10 cells proportion was associated with tumor size, depth of invasion, lymph node metastasis, and TNM stage in CRC. Kaplan–Meier analysis indicated that CRC patients with high B10 cells proportion suffered worse overall survival than those with low B10 cells proportion. Multivariate analysis revealed that the proportion of B10 cells was an independent prognostic indicator for CRC patients.Conclusion: Our results indicate that the proportion of circulating B10 cells is an independent prognostic factor for patients with CRC and thus may help guide the clinical decision in CRC.